An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Exclusion Criteria

• •1. Hypersensitivity to active ingredients or any of the excipients in tipranavir or ritonavir
• •2. Required use of restricted medications.
• •3. Female patients of childbearing potential who have a positive pregnancy test at baseline or are breast feeding.
• •4. Any medical condition which in the opinion of the investigator would interfere with the patients' ability to participate in or adhere to the requirements of this protocol.
• •5. Use of other investigational drugs, within 30 days prior to TPV boosted with ritonavir initiation and for the duration of study participation
• •6. Hepatic impairment evidenced by the following baseline laboratory findings:
• •* AST or ALT more than 5X ULN or total bilirubin more than 3.5X ULN
• •* AST or ALT more 2.5X ULN and total bilirubin more 2X ULN